In light of evidence suggesting that both metformin and ω-3 can improve the metabolic states of children with obesity, Juarez-Lὁpez et al. focused their work on administering these drugs to IR children with obesity to assess their effects on fasting glucose, insulin, HOMA-IR index, lipid profile, and BMI. The gene discussed is INS; the disease is obesity due to melanocortin 4 receptor deficiency.